Duque PL, Arrivillaga-Henríquez J, Enríquez S, Ron-Garrido L, Benítez W, Navarro JC. Spatial-Temporal Analysis of Lutzomyia trapidoi and Lutzomyia reburra (Diptera: Phlebotominae), in Rural Tourist Locations, Biosphere Reserve and Leishmaniasis Endemic Area, Ecuador. J Med Entomol. 2020;57(6):1905–12.

Article  PubMed  Google Scholar 

Gurel MS, Tekin B, Uzun S. Cutaneous leishmaniasis: a great imitator. Clin Dermatol. 2020;38(2):140–51.

Article  PubMed  Google Scholar 

Mathison BA, Bradley BT. Review of the Clinical Presentation, Pathology, Diagnosis, and Treatment of Leishmaniasis. Lab Med. 2023;54(4):363–71.

Article  PubMed  Google Scholar 

Montaner-Angoiti E, Llobat L. Is leishmaniasis the new emerging zoonosis in the world? Vet Res Commun. 2023;47(4):1777–99.

Article  PubMed  Google Scholar 

Tarnas MC, Abbara A, Desai AN, Parker DM. Ecological study measuring the association between conflict, environmental factors, and annual global cutaneous and mucocutaneous leishmaniasis incidence (2005–2022). PLoS Negl Trop Dis. 2024;18(9):e0012549.

Article  PubMed  PubMed Central  Google Scholar 

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Global Burden of Disease Study 2019. Global Burden of Disease Study 2019. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204–22.

Article  Google Scholar 

Ruiz-Postigo J, Jain S, Madjou S, Virrey J et al. Global leishmaniasis surveillance, 2022: assessing trends over the past 10 years. [Internet]. 2023 [cited 2025 May 28]. Available from: https://www.who.int/publications/i/item/who-wer9840-471-487

de Vries HJC, Schallig HD, Cutaneous Leishmaniasis. Cutaneous Leishmaniasis. A 2022 Updated Narrative Review into Diagnosis and Management Developments. Am J Clin Dermatol. 2022;23(6):823–40.

Article  PubMed  PubMed Central  Google Scholar 

Abadías-Granado I, Diago A, Cerro PA, Palma-Ruiz AM, Gilaberte Y. Leishmaniasis cutánea y mucocutánea. Actas Dermo-Sifiliográficas. 2021;112(7):601–18.

Article  Google Scholar 

Pradhan S, Schwartz RA, Patil A, Grabbe S, Goldust M. Treatment options for leishmaniasis. Clin Exp Dermatol. 2022;47(3):516–21.

Article  PubMed  Google Scholar 

Organización Panamericana de la Salud. Directrices para el tratamiento de las leishmaniasis en la Región de las Américas. Directrices para el tratamiento de las leishmaniasis en la Región de las Américas. Segunda edición [Internet]. Segunda edición. Washington, DC: Organización Panamericana de la Salud. 2022 [cited 2025 May 28]. Available from: https://iris.paho.org/bitstream/handle/10665.2/56121/9789275325032_spa.pdf?sequence=15&isAllowed=y

Organización Panamericana de la Salud. Leishmaniasis en las Américas: recomendaciones para el tratamiento [Internet]. Organización Panamericana de la Salud. 2013. Available from: https://iris.paho.org/handle/10665.2/7704

Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011;118(2):87–96.

Article  PubMed  Google Scholar 

Duque MC, de O, Vasconcellos É, de Pimentel CFE, Lyra MIF, Pacheco MR, de Marzochi SJB, et al. A,. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis. Rev Soc Bras Med Trop. 2016;49(6):774–6.

Article  PubMed  Google Scholar 

Organización Panamericana De La Salud. Síntesis de evidencia y recomendaciones: directrices para el tratamiento de las leishmaniasis en la Región de las Américas. Rev Panam Salud Publica [Internet]. 2023 Apr 28 [cited 2025 May 28];47:1. Available from: https://iris.paho.org/bitstream/handle/10665.2/57405/v47e432023.pdf?sequence=1&isAllowed=y

Brito NC, Machado de Assis TS, Rabello A, Cota G. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis. PLoS Negl Trop Dis. 2019;13(12):e0007856.

Article  PubMed  PubMed Central  Google Scholar 

Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One. 2017;12(9):e0184777.

Article  PubMed  PubMed Central  Google Scholar 

Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis. 2013;56(90):1255–60.

Article  PubMed  Google Scholar 

Rojas Cabrera E. Aplicación Intralesional de Antimoniales en el Tratamiento de Leishmaniasis Cutánea. GMB [Internet]. 2022 Jun 30 [cited 2025 May 28];45(1):6–11. Available from: https://gacetamedicaboliviana.com/index.php/gmb/article/view/4

Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves da Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil – an area of Leishmania (V.) braziliensis transmission. International Journal of Dermatology [Internet]. 1997 [cited 2025 May 28];36(6):463–8. Available from: https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1046/j.1365-4362.1997.00188.x

Fernandes HJ. Análise da toxicidade relacionada ao uso intralesional de antimoniato de meglumina para tratamento da leishmaniose cutânea localizada. 2019 [cited 2025 May 28]; Available from: https://www.arca.fiocruz.br/handle/icict/35337

Ramalho DB, da Silva RE, de Senna MCR, Moreira HSA, Pedras MJ, de Avelar DM et al. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial. Mem Inst Oswaldo Cruz [Internet]. 2018 Jun 21 [cited 2025 May 28];113(9):e180200. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012678/

Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. J Infect Public Health. 2013;6(2):120–4.

Article  PubMed  Google Scholar 

Meléndez-Oviedo V, González-Matute M, Sierra M, Alger J, Zúniga C, López-Lutz E. Estudio comparativo entre antimoniato de meglumina intralesional versus tratamiento convencional intramuscular en el manejo de leishmaniasis cutanea atipica. 2006;9.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 2019 [cited 2025 May 28]. Available from: https://training.cochrane.org/handbook

Page M, McKenzie J, Bossuyt P, Boutron I et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | The BMJ [Internet]. 2021 [cited 2025 May 28]. Available from: https://www.bmj.com/content/372/bmj.n71

PROSPERO [Internet]. [cited 2025 May 28]. Available from: https://www.crd.york.ac.uk/prospero/#aboutpage

Higgins JPT, Altman DG, Gotzsche PC, Juni P et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials | The BMJ [Internet]. 2011 [cited 2025 May 28]. Available from: https://www.bmj.com/content/343/bmj.d5928

Sterne JAC, Higgins J et al. The Risk Of Bias In Non-randomized Studies – of Interventions, Version 2 (ROBINS-I V2) assessment tool. [Internet]. 2024 [cited 2025 May 28]. Available from: https://www.riskofbias.info/welcome/robins-i-v2

Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook [Internet]. 2013 [cited 2025 May 28]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html

Lyra MR, Oliveira LFA, Schubach AO, Sampaio RNR, Rodrigues BC, Hueb M, et al. A randomized, controlled, noninferiority, multicenter trial of systemic vs intralesional treatment with meglumine antimoniate for cutaneous leishmaniasis in Brazil. Clin Infect Dis. 2023;77(4):574–82. https://doi.org/10.1093/cid/ciad253.

Article  PubMed  Google Scholar 

Abdellahi L, Hejazi SH, Amirmozafari N, Sotoodehnejadnematalahi F. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran. Arch Iran Med [Internet]. 2020 Nov 1 [cited 2025 May 28];23(11):740–8. Available from: https://journalaim.com/Article/aim-13565

Karamian M, Faroghi Bojd MS, Salehabadi A, Hemmati M, Barati DA. Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. Easter Mediterr Health J. 2015;21(4):280–6.

Article  Google Scholar 

Tareen A, Ahmad SA, Khan I. Comparison of the efficacy of intralesional versus intramuscular injection Meglumine Antimoniate in the treatment of sores of Cutaneous Leishmaniasis [Internet]. Int J Pathol; 2016. Available from: https://jpathology.com/index.php/OJS/article/view/215

Alkhawajah AM, Larbi E, al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol [Internet]. 1997;91(8):899–905. Available from: https://pubmed.ncbi.nlm.nih.gov/9579209/

Munir A, Janjua SA, Hussain I. Clinical Efficacy of Intramuscular Meglumine Antimoniate Alone and in Combination with Intralesional Meglumine Antimoniate in the Treatment of Old World Cutaneous Leishmaniasis. Acta Dermatovenerol Croat. 2008;16(2):60–4.

PubMed  Google Scholar 

Rodrigues BC, Ferreira MF, Barroso DH, Motta JOC, de Paula CDR, Porto C, et al. A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist. 2020;14:257–63.

Article  PubMed  PubMed Central  Google Scholar 

Oliveira-Ribeiro C, Pimentel MIF, Oliveira L, de Vasconcellos FA, de CF É. e, An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil | PLOS Neglected Tropical Diseases [Internet]. 2021 [cited 2025 May 28]. Available from: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009734

Limachi-Choque JW, Rojas-Cabrera E, Verduguez-Orellana A, Eid-Rodríguez D. El tratamiento intralesional de Leishmaniasis cutánea es seguro frente al riesgo de complicaciones mucosas? Gaceta Médica Boliviana [Internet]. 2020 Aug [cited 2025 May 28];43(1):18–22. Available from: http://www.scielo.org.bo/scielo.php?script=sci_abstract&pid=S1012-29662020000100004&lng=es&nrm=iso&tlng=es

Martin R, Lee VR. Antimony Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 May 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK608003/

Vasconcellos ECF, Fernandes MI, Schubach A, Am J, Trop Med H et al. 2012 [cited 2025 May 28]. Intralesional Meglumine Antimoniate for Treatment of Cutaneous Leishmaniasis Patients with Contraindication to Systemic Therapy from Rio de Janeiro (2000 to 2006) in: The American Journal of Tropical Medicine and Hygiene Volume 87 Issue 2 (2012). Available from: https://www.ajtmh.org/view/journals/tpmd/87/2/article-p257.xml

MINISTERIO DE SALUD. ALERTA DIGEMID No 45- 2019 RECOMENDACIONES PARA PREVENIR POSIBLES REACCIONES ADVERSAS PRODUCIDAS POR EL USO DE ANTIMONIALES PENTAVALENTES EN EL TRATAMIENTO DE LA LEISHMANIOSIS [Internet]. 2019. Available from: https://www.digemid.minsa.gob.pe/Archivos/Alertas/2019/ALERTA_45-19.pdf

Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. The Lancet Infectious Diseases [Internet]. 2007 Sep 1 [cited 2025 May 28];7(9):581–96. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(07)70209-8/abstract